Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1
Authors
Keywords
-
Journal
Neurology-Genetics
Volume 7, Issue 5, Pages e616
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-08-07
DOI
10.1212/nxg.0000000000000616
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selumetinib in Children with Inoperable Plexiform Neurofibromas
- (2020) Andrea M. Gross et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
- (2019) Jason Fangusaro et al. LANCET ONCOLOGY
- Trametinib for progressive pediatric low-grade gliomas
- (2018) Maria Kondyli et al. JOURNAL OF NEURO-ONCOLOGY
- Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells
- (2017) Jiho Choi et al. NATURE
- A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
- (2017) Anuradha Banerjee et al. NEURO-ONCOLOGY
- Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
- (2016) Eva Dombi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differences in Parent and Teacher Rating of Everyday Executive Function in Pediatric Brain Tumor Survivors
- (2014) G. C. Wochos et al. CLINICAL NEUROPSYCHOLOGIST
- ERK Inhibition Rescues Defects in Fate Specification of Nf1-Deficient Neural Progenitors and Brain Abnormalities
- (2012) Yuan Wang et al. CELL
- Neurofibromatosis Type 1: Modeling CNS Dysfunction
- (2012) D. H. Gutmann et al. JOURNAL OF NEUROSCIENCE
- Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior
- (2011) Jonathan M. Payne et al. CHILD NEUROPSYCHOLOGY
- Lovastatin as Treatment for Neurocognitive Deficits in Neurofibromatosis Type 1: Phase I Study
- (2011) Maria T. Acosta et al. PEDIATRIC NEUROLOGY
- Molecular and Cellular Mechanisms of Learning Disabilities: A Focus on NF1
- (2010) C. Shilyansky et al. Annual Review of Neuroscience
- Engagement of the PFC in consolidation and recall of recent spatial memory
- (2010) W. C. Leon et al. LEARNING & MEMORY
- Neurofibromin regulates corticostriatal inhibitory networks during working memory performance
- (2010) C. Shilyansky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The molecular and cellular biology of enhanced cognition
- (2009) Yong-Seok Lee et al. NATURE REVIEWS NEUROSCIENCE
- Neurofibromin Regulation of ERK Signaling Modulates GABA Release and Learning
- (2008) Yijun Cui et al. CELL
- Effect of Simvastatin on Cognitive Functioning in Children With Neurofibromatosis Type 1
- (2008) Lianne C. Krab JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Health-Related Quality of Life in Children with Neurofibromatosis Type 1: Contribution of Demographic Factors, Disease-Related Factors, and Behavior
- (2008) Lianne C. Krab et al. JOURNAL OF PEDIATRICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started